2008
Dose-dependent reduction of hazardous alcohol use in a placebo-controlled trial of naltrexone for smoking cessation
O'Malley SS, Krishnan-Sarin S, McKee SA, Leeman RF, Cooney NL, Meandzija B, Wu R, Makuch RW. Dose-dependent reduction of hazardous alcohol use in a placebo-controlled trial of naltrexone for smoking cessation. The International Journal Of Neuropsychopharmacology 2008, 12: 589-597. PMID: 18796184, PMCID: PMC3094855, DOI: 10.1017/s146114570800936x.Peer-Reviewed Original ResearchConceptsHazardous drinkingSmoking cessationFavorable side effect profileDose-ranging clinical trialAlcohol useEffects of NTXPlacebo-controlled trialDose-ranging trialSide effect profileTransdermal nicotine patchOpiate antagonist naltrexoneDose-dependent reductionComponent of treatmentHazardous alcohol useOral NTXSecondary outcomesNicotine patchPrimary outcomeAntagonist naltrexoneCombination therapyClinical trialsBaseline predictorsOral preparationsHazardous drinkersNTX
2002
Screening for health behaviors in ambulatory clinical settings Does smoking status predict hazardous drinking?
Kranzler HR, Amin H, Cooney NL, Cooney JL, Burleson JA, Petry N, Oncken C. Screening for health behaviors in ambulatory clinical settings Does smoking status predict hazardous drinking? Addictive Behaviors 2002, 27: 737-749. PMID: 12201381, DOI: 10.1016/s0306-4603(01)00206-4.Peer-Reviewed Original ResearchConceptsCurrent smoking statusSmoking statusFagerstrom Tolerance QuestionnaireHazardous drinkingCurrent smokersAlcohol consumptionCurrent alcohol consumptionAmbulatory clinical settingCurrent smokingPast smokersDental patientsMale genderYears of educationSmoking behaviorHealth behaviorsYounger ageMajority of studiesClinical settingScreening instrumentSmokersSmokingTolerance QuestionnairePast historySignificant predictorsDrinking